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Abstract 29 
 30 
In continuity with the review dealing with differences by gender in non-sexual 31 
organs [1], this review collects data on the proteomes of the sexual organs as 32 
involved in human reproduction, under both physiological and pathological 33 
conditions. It also collects data on the tissue structures and biological fluids 34 
typical of pregnancy, such as placenta and amniotic fluid, as well as what may 35 
be tested on preimplantation embryos during medically assisted reproduction. 36 
The review includes as well mention to all fluids and secretions connected 37 
with sex organs and/or reproduction, including sperm and milk, to exemplify 38 
two distinctive items in male and female physiology. 39 
 40 
 41 
Significance 42 
 43 
The causes of infertility are only incompletely understood; the same holds for 44 
the causes, and even the early markers, of the most frequent complications of 45 
pregnancy. To these established medical challenges, present day practice 46 
adds new issues connected with medically assisted reproduction. Omics 47 
approaches, including proteomics, are building the database for basic 48 
knowledge to possibly translate into clinical testing and eventually into 49 
medical routine in this critical branch of health care. 50 
 51 
 52 
Highlights 53 
 54 
x The review lists proteomic data on sexual apparatuses and 55 
reproductive function 56 
x Focus is on our species and both tissues and biological fluids are dealt 57 
with 58 
x Both physiological and pathological conditions are analyzed 59 
x Pregnancy and its complications are dealt with in detail 60 
 61 
  62 
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1 Introduction 63 
 64 
The subtitle of this review reads ‘Which proteins in sexual organs’. Sexual 65 
organs, however, is a shorthand to mean not only the tissue structures of the 66 
gonads but also all of the fluids and secretions connected with them. Our 67 
writing also considers all structures and fluids involved in pregnancy and in its 68 
outcome e.g. placenta and amniotic fluid, but also colostrum and milk, as well 69 
as specimens connected with medically assisted reproduction. As in [1], data 70 
are taken as far as possible from human studies but information from work on 71 
animals is included when sample procurement from our species would be 72 
impractical or unethical. 73 
The number of papers that we survey in this review, focusing on a small 74 
number of specialized organs, matches that in the first one in this thematic 75 
issue, dealing with all other parts of our body [1]. As we have already stressed, 76 
the interest for male/female differences in non-sexual organs is recent and the 77 
number of publications is comparatively small overall and even more so when 78 
individual topics are considered. Instead, understanding the physiology at the 79 
basis of human reproduction is an established research field: reference to 80 
these studies is being made when monitoring pregnancy progression as well 81 
as when addressing the issues of infertility and, more recently, of medically 82 
assisted reproduction. 83 
 84 
We present in this review proteomics data for both, physiological and 85 
pathological conditions. For the latter, we specifically focus on infertility and 86 
the connected issue of medically assisted reproduction, with only some 87 
mention to a different and wider topic – cancer of uterus, breast and prostate. 88 
Before proceeding with the writing, let’s shortly frame the issue of infertility in 89 
either sex. As reviewed in [2], the most common conditions observed in 90 
infertile women (polycystic ovary syndrome, endometriosis, anomalies of the 91 
female reproductive system) are multifactorial; genetic infertility is instead 92 
connected with mutations in FMR1, FOXL2, GLAT, or POLG. In infertile men, 93 
the main gonosomal aneuploidy is represented by Klinefelter syndrome 94 
(47,XXY). Mutations in CFTR can result in congenital bilateral absence of the 95 
vas deferens, or obstructive azoospermia. Various Y chromosome 96 
microdeletions cause non-obstructive azoospermia or severe oligospermia; 97 
the number of chromosomal aberrations inversely correlates with sperm count. 98 
Medically assisted reproduction involves a growing number of infertile 99 
individuals. The most recent data for Europe, reviewed in [3], show the 100 
average number of assisted reproductive technologies cycles in 2010 to have 101 
been around 8,000 per million women 15–45 years of age, with peaks close to 102 
15,000 per million in some countries. This situation poses new challenges to 103 
research, clinical practice, ethics, legal issues and policy as listed in the 104 
subtitle to the comprehensive review by Harper et al. [2]. Some of these 105 
challenges are open to contribution from omics technologies. For instance, 106 
screening on preimplantation embryos [4] has moved concern and diagnostic 107 
procedures to the phase that precedes the beginning of gestation. This adds 108 
to the routine monitoring of pregnancies and to the continuing search for 109 
predictors/early markers of congenital disease of the fetus as well as of 110 
pregnancy complications, including pre-eclampsia/eclampsia, pregnancy-111 
induced hypertension, recurrent pregnancy loss and pre-term delivery. 112 
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 113 
The proteomics data on sex organs et al. in both physiological and 114 
pathological conditions along the above outline are thus listed and 115 
commented in the following. Ladies first. 116 
 117 
2 Which proteins in sexual organs? 118 
 119 
2.1 Female items 120 
 121 
2.1.1 (Mainly) changes along the menstrual cycle 122 
 123 
Hormonally-induced variations can be recognized in the composition of serum 124 
and urine along the menstrual cycle (dealt with in [1]): on this basis, it may be 125 
safely assumed that even deeper changes should be observed in the 126 
structures more closely connected with sexual functions. 127 
In this perspective, the nipple aspirate fluid [5-7] was collected weekly from 128 
both breasts of a group (12) of premenopausal women during two months 129 
while measuring their serum levels of luteinizing hormone, follicle stimulating 130 
hormone and estradiol to determine the phase of each menstrual cycle. The 131 
individual samples were processed through SELDI; it was concluded that 132 
nipple aspirate fluid proteomic profile does not vary substantially during the 133 
menstrual cycle [8]. 134 
Another non-invasively collected sample, endometrial fluid, was so far 135 
analyzed only during the secretory phase of the menstrual cycle. The 136 
combination of three analytical strategies, gel-based and gel-free, led to the 137 
identification of > 800 different proteins [9]. The analysis of a coarser type of 138 
sample, cervico-vaginal fluid as a mixture of fluids originating from the 139 
vagina, cervix, endometrium, and oviduct, collected without control for 140 
subject’s time point during the menstrual cycle led to the identification of a 141 
total of 685 proteins, mainly extracellular or membrane components, with 142 
several defense-related proteins (azurocidin, defensins, dermcidin, 143 
haptoglobin and lactoferrin) and many serine and cysteine proteases [10].  144 
 145 
The endocervical mucus was studied before, during, and after ovulation. 146 
Among the 194 identified proteins, 3 gel-forming (MUC5B, MUC5AC, and 147 
MUC6) and 2 transmembrane mucins (MUC16 and MUC1) were detected. 148 
The analysis of mucin O-glycosylation showed an increase of GlcNAc-149 
6GalNAcol core 2 structures and a relative decrease of NeuAc residues 150 
around ovulation, whereas NeuAc-6GalNAcol and NeuAc-3Gal- epitopes are 151 
typical for the non-ovulatory phases [11]. 152 
Evaluation of differentially regulated proteins between proliferative and 153 
secretory phase in the proteome of human endometrium [12] was carried out, 154 
with different procedures, on biopsies (ca.100 mg), resulting in the 155 
identification of 8 proteins [13] and on eutopic endometrium samples collected 156 
during routine surgical procedures, resulting in the identification of 49 proteins 157 
[14]. The differences in the narrow temporal interval between the pre-158 
receptive and receptive phases were explored on bioptic material, resulting in 159 
the identification of 31 proteins [15]. Not only the proteomic protocols but also 160 
the procedures for phasing the endometrial samples and the sample timing 161 
itself differed from one report to the other. Likely as a result of these 162 
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differences the overlap between the reported results is minimal, even when 163 
disregarding the difference between subunits of complex proteins or protein 164 
isoforms: as shown in Supplementary Table 1, not more than six proteins are 165 
found repeatedly in the three studies; opposite regulation is sometimes 166 
reported. The only common finding is with fibrinogen, a protein involved in 167 
hemostasis and wound repair but whose connection with hormonal status is 168 
well documented. Indeed, systematic cyclical variations of fibrinogen levels 169 
along the menstrual cycle have been reported, but individual cycling was 170 
small in comparison with intra-individual variability [16]. Morphology and 171 
viscoelastic properties of fibrin clots were found to depend on the levels of 172 
estrogen and progesterone [17]. In post-menopausal women without 173 
medication, fibrinogen correlates with endogenous estrogen levels, the 174 
association being stronger among women with body mass index over 25 175 
kg/m2 [18]. Conversely, the Postmenopausal Estrogen/Progestin Interventions 176 
(PEPI) trial demonstrated that hormone replacement therapy could limit the 177 
increase in fibrinogen in post menopausal women [19]. Maternal fibrinogen is 178 
essential for successful pregnancy [20]; in rats, fibrinogen gamma is 179 
specifically increased in uterine epithelial cells at the time of implantation, with 180 
higher dimer levels [21]. 181 
The proteins of the longest list may be classified according to their function as 182 
molecular chaperones (30%), structural proteins (27%), proteins involved in 183 
RNA biogenesis, protein biosynthesis and nuclear organization (14%), 184 
proteins involved in signal transduction (12%), immunity-related protein (10%) 185 
and mitochondrial enzymes (4%) [14]: such a variety of aspects is to 186 
document the extensive remodeling occurring during this crucial biological 187 
stage. 188 
In a previous shotgun investigation, only 2 proteins with unquestionable 189 
differential regulations in the secretory vs the proliferative endometrium could 190 
be identified (glutamate NMDA receptor submit zeta 1 and FRAT1, not in the 191 
above lists) [22]. 192 
When the endometrial tissue (ca. 60 nL in volume) was laser-microdissected 193 
into glandular epithelium and stroma, and the tryptic digests were analyzed by 194 
LC-MS/MS [23], the findings in the two compartments were vastly dissimilar. 195 
In the epithelial cells from the proliferative endometrium 318 proteins were 196 
identified as significantly altered vs the secretory endometrium; 145 of these 197 
proteins had a role in cellular growth and proliferation pathways. Conversely, 198 
only 19 proteins were significantly altered in the stromal samples harvested 199 
from the proliferative vs the secretory endometrium, and tissue development 200 
was identified as the most significantly enriched pathway. 201 
From this summary, we must conclude that, unfortunately, the above 202 
investigations have failed to provide a consensus differential pattern; however, 203 
their number, together with the heterogeneity of the sampling procedures and 204 
of the analytical protocols reflect a strong interest on this specimen, in at least 205 
two perspectives – endometriosis and medically assisted reproduction.  206 
Before closing this section, we have to mention one more type of specimen, 207 
menstrual blood, whose composition may be of interest both to pathology 208 
(infertility and uterine pathologies) and to forensic science (distinction 209 
between menstrual blood and circulating blood). The samples collected during 210 
the central days of the menstruation were analyzed along five protocols. More 211 
than 1,000 proteins overall were identified, one third of which (361) by at least 212 
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two methods. When the menstrual blood proteome was compared with those 213 
of circulating blood (1774 proteins) and vaginal fluid (823 proteins), 385 214 
components – most of them involved in processes typical of the endometrial 215 
cycle – were found unique to menstrual blood. 216 
 217 
2.1.2 Changes in pregnancy 218 
 219 
As we did in 2.1.1, we first review the proteomic evidence on biological 220 
fluids – to conclude, once more, that data are all but systematic.  221 
The closest approximation to an in-depth evaluation of the changes induced 222 
by pregnancy in serum may be found in a report assessing changes in 223 
relative protein abundance between paired serum samples, collected in the 224 
same pregnant women during first and third trimester and analyzed by 2DE-225 
DIGE [24]. Significant differences were detected in ca. 10% of the resolved 226 
spots; the identified proteins were found associated with gestational age, 227 
cytoskeletal remodeling, blood pressure regulation, lipid and nutrient transport, 228 
and inflammation. Two proteins were detected for which there was either only 229 
transcriptional evidence of existence (pregnancy-specific beta-1-glycoprotein 230 
4) or no information had been available about differential abundance along 231 
pregnancy (gelsolin). Changes in abundance of proteins in serum that are 232 
associated with syncytiotrophoblasts (beta-2-glycoprotein I, gelsolin, and 233 
pregnancy-specific beta-1-glycoprotein 1) probably reflect dynamics of the 234 
proportion of placental proteome shed into maternal circulation. 235 
In contrast to the lack of overall evaluations on serum, focused studies in the 236 
course of gestational time have been devoted to subsets of serum proteins. 237 
One of these distinctive classes is that of lipoproteins, in keeping with the 238 
metabolic shift from the glycolytic to the lipolytic pathway in pregnant women. 239 
Apolipoprotein C-II is mainly distributed in the HDL of normolipidemic 240 
individuals, whereas it is predominantly found in the VLDL and LDL of 241 
hypertriglyceridemic individuals; both the mature proteolytically cleaved 242 
protein and its proform can activate lipoprotein lipase. Mature apo C-II 243 
represents around 1/15 of total apo C-II in early and 1/3 in late gestation (7x 244 
increase); pro-apo C-II only increases in the third trimester (by 40% vs first 245 
trimester). Singly and doubly sialylated apo C-III subtypes linearly increase 246 
with gestational age (apo C-III2, 3x, and apo C-III3, 2x). None of the other 247 
apos changes during normal pregnancy but modified apo A-II forms are 248 
significantly elevated in plasma from mothers who delivered prematurely 249 
relative to term controls [25]. In a mother/fetus comparison, maternal HDLs 250 
appear to mainly belong to the dense HDL3, fetal HDL to the light HDL2 sub-251 
fraction. Some proteins are statistically elevated in fetal HDL (apoE, proteins 252 
involved in coagulation and in transport processes), some are decreased or 253 
absent (apoA-I, apoL and paraoxonase 1); the quantity of CETP is similar but 254 
its enzymatic activity is reduced to ½ in fetal HDL. Overall, with their distinct 255 
composition, fetal HDLs are associated with decreased anti-oxidative and 256 
innate immunity properties [26]. 257 
A second focused study deals with glycoproteins, or better with their N-linked 258 
glycans, which means with the serum N-glycome. Changes in the 259 
glycosylation during pregnancy were first reported for a model protein, 260 
transferrin, as early as in 1988 [27]. It is known that specific glycoforms are 261 
involved in recognition events; this is true also of the key molecules involved 262 
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in the innate and adaptive immune response [28]. Pregnancy requires partial 263 
suppression of the immune system to ensure maternal-fetal tolerance. Protein 264 
glycosylation, and especially terminal sialic acid linkages, are of prime 265 
importance in regulating the pro- and anti-inflammatory immune responses. A 266 
survey on all the serum proteins shows that the levels of extensively sialylated 267 
bi-, tri-, and tetra-antennary glycans increase during pregnancy, while 268 
biantennary glycans, with no more than one sialic acid, decrease [29]. In a 269 
more detailed investigation, a very large number of glycans (77) was followed 270 
through 6 time points, during and after pregnancy. An increase during 271 
pregnancy and a decrease after delivery were observed for both alpha-2,3- 272 
and alpha-2,6-linked sialylation, with a different time evolution after delivery 273 
[30]. When aiming at Igs, marked differences in glycosylation exist between 274 
Fab and Fc (higher levels in Fab of galactosylation and sialylation, incidence 275 
of bisecting GlcNAc, and presence of high mannose structures, lower levels of 276 
fucosylation). During pregnancy Fab N-glycan sialylation is higher and 277 
bisection is lower relative to postpartum time points, and nearly complete 278 
galactosylation of Fab glycans may be observed throughout. Fc undergoes 279 
similar changes in glycosylation [31]. 280 
 281 
Urine was investigated at a single time point (by comparing the pattern one 282 
day before and 30 days after vaginal delivery). Analysis through 1-DE and LC-283 
MS/MS lead to the identification of > 800 proteins common to both conditions 284 
vs ca. 600 proteins unique to pregnancy and twice as many unique to non-285 
pregnancy samples. Of the 105 identified phosphoproteins, 14 were up-286 
regulated and 2 were down-regulated in urine samples from women just 287 
before vaginal delivery [32]. 288 
 289 
Two types of secretions have also been investigated. One is cervico-vaginal 290 
fluid in healthy, pregnant women at term. After 2-DE, 15 proteins could be 291 
identified with various functions (transport and calcium binding, fatty acid 292 
metabolism, proteinase inhibitors, defense against inflammation and oxidative 293 
stress) [33]. Another is cervical mucus plug, the sealant of the uterine cavity 294 
during pregnancy, which was obtained from women in labor at term and 295 
analyzed by LC-MS/MS. Several proteins, which have been described neither 296 
in the cervical mucus of non-pregnant women nor in cervicovaginal fluids, 297 
were identified, such as CD81 antigen and pregnancy zone protein. Gene 298 
ontology analysis of identified proteins showed significant enrichment of 299 
several biological processes including activation of plasma proteins involved 300 
in acute inflammatory response and positive regulation of cholesterol 301 
esterification [34]. 302 
 303 
As for tissues, it is all but surprising that the number of human samples that 304 
could ever be assessed is very small. One notable exception is myometrium 305 
(uterine smooth muscle), whose S-nitrosoproteome was on focus trying to 306 
understand the regulation of uterine contraction-relaxation in view of a 307 
possible treatment for preterm labor. The study was based on the hypothesis 308 
that myometrial NO-mediated relaxation is dependent on the S-nitrosation of 309 
specific and critical proteins. Myometrium biopsies were obtained from three 310 
groups of mothers undergoing elective cesarean section (laboring preterm, 311 
laboring at term, at term & not laboring) and then processed through a 312 
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protocol starting with incubation with S-nitrosoglutathione. More than 100 313 
proteins were found to be S-nitrosated in one or more states of human 314 
pregnancy; as shown by Figure 1, some of them are present at higher 315 
concentration in samples from laboring, some in samples from non-laboring 316 
mothers [35]. 317 
 318 
Other studies have involved instead material from animal species: rat for 319 
corpus luteum [36], sheep for endometrium (aglandular caruncular vs 320 
glandular intercaruncular areas) [37] and extracellular vesicles (exosomes 321 
and microvesicles, of endosomal and plasma membrane origin, that mediate 322 
conceptus-maternal interactions during early pregnancy) [38]. 323 
 324 
Back to our species, a number of investigations have addressed the issue of 325 
fertility vs infertility. 2DE-DIGE on uterine lavages collected from fertile and 326 
infertile women during the mid-secretory phase, and from fertile women during 327 
the mid-proliferative phase, detected 18 differential spots between fertile and 328 
infertile women: all of them, however, correspond to major serum proteins [39]. 329 
A more specific picture of the events occurring at the point of the first mother-330 
embryo contact may be provided by an in vitro system. ECC1 is an 331 
endometrial adenocarcinoma epithelial cell line that may be taken as model of 332 
the endometrial luminal epithelium. ECC1 cells were treated with estrogen 333 
in the absence/presence of progesterone to mimic the proliferative and 334 
secretory phases of the menstrual cycle, and hCG was used to mimic the 335 
embryonic signal at the time of conception. Proteomic analysis (1-DE and LC-336 
MS/MS) on cell lysates identified ca.150 progesterone-regulated cellular 337 
proteins, with further ca.200 significantly altered in response to hCG; cellular 338 
changes were associated with metabolism, basement membrane and cell 339 
connectivity, proliferation and differentiation. In the shotgun analysis of soluble 340 
secretome 123 proteins were found significantly altered by progesterone, and 341 
43 proteins altered by hCG, including proteins associated with cellular 342 
adhesion, extracellular-matrix organization, developmental growth, growth 343 
factor regulation, and cell signaling [40]. 344 
In a symmetric approach, with in vitro fertilization through intracytoplasmic 345 
sperm injection cycles and culture of the zygotes before in utero transfer, the 346 
secretome of pre-implantation embryos could be evaluated from the spent 347 
media. Separation by nano-HPLC and identification via tandem nano-ESI MS 348 
led to the identification of unique proteins in both the positive- and negative-349 
implantation groups [41]. A more recent investigation focused on the 350 
quantitation of few cytokines combined with time-lapse morphokinetic 351 
analysis: higher implantation rates were found associated with the presence 352 
of IL-6 and a cell cycle duration of 5-12 h [42]. As already mentioned in [1], 353 
during the earliest phases of their existence, female embryos have two active 354 
X chromosomes, which entails a different proteome vs male embryos. Direct 355 
analysis of the secretome as above, or indirect quantitation of cellular 356 
functions under the influence of X-linked genes/proteins, may be a means of 357 
non-invasively determining the sex of an embryo (as an alternative to 358 
blastomere biopsy followed by the identification of the sex chromosomes 359 
through either FISH, PCR, SNP arrays or comparative genomic hybridization) 360 
[43]. Blastocoel fluid, isolated by micromanipulation from surplus blastocysts, 361 
was found to contain several heat shock proteins as well as proteins that 362 
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regulate ciliary assembly and function, together with zona pellucida proteins, 363 
vitamin D-binding protein, and retinol-binding protein 4 [42]. Knowledge on the 364 
composition of this liquid could possibly assist defining optimal culture 365 
conditions of human embryonic stem cells for possible applications in 366 
regenerative medicine. Similar investigations on preimplantation embryos 367 
have been carried out also on bovine specimens: blastocoel fluid and 368 
blastocyst cells, around day 6 [44], but also ovoid and elongated embryos, 369 
containing the primitive yolk sac fluid, as late as at day 13, after in vitro 370 
produced embryos had been transferred into a recipient heifer and cultured in 371 
vivo during 7 further days (embryos were recovered by flushing both uterine 372 
horns after slaughter) [45]. 373 
 374 
Most reports dealing with placenta address the differences between 375 
physiological and pathological conditions, as detailed in the following; a few 376 
refer instead to baseline conditions. As an example, Mushahary et al. 377 
performed 2DE-MS/MS on tissue from full term delivery and then integrated 378 
their identifications with results from earlier analyses, compiling a 379 
comprehensive dataset that also included function and clinical relevance of 380 
each item [46]. There are obvious ethical and practical limitations to the 381 
procurement of material along the progression of human pregnancy. One 382 
investigation addressing the difference between early and late weeks 383 
compared late first-trimester placentas from pregnant women referring for 384 
legal abortion due to mother indication (such as heart disease) to normal full-385 
term placentas from normotensive mothers who underwent an elective-term 386 
cesarean section around the gestational age of 38 weeks. The functions of 387 
the differential proteins (4 more and 7 less abundant in late first-trimester 388 
placentas) range between energy metabolism, redox regulation, chaperoning, 389 
and muscle contraction [47]. Using a mouse model, it was instead possible to 390 
carry out at two time points (embryonic day 7.5 and 10.5) an in-depth 391 
comparative proteomic analysis of extraembryonic tissues and placentas after 392 
either in vivo fertilization and development or in vitro fertilization and culture. 393 
More than 150 differential proteins were identified in each type of specimen; 394 
many were functionally associated with genetic information processing, such 395 
as impaired de novo DNA methylation, as well as post-transcriptional, 396 
translational and post-translational dysregulation; such findings were 397 
confirmed by hypomethylation of the genetic material and by a lower level of 398 
correlation between transcriptome and proteome in the in vitro samples. Other 399 
differential proteins were involved in energy and amino acid metabolism, 400 
cytoskeleton organization and transport, vasculogenesis and angiogenesis: 401 
disturbance of these processes and pathways is likely to be associated with 402 
embryonic intrauterine growth restriction, an enlarged placenta, and impaired 403 
labyrinth morphogenesis observed in the in vitro samples [48]. 404 
Two regions may be recognized in the placenta: the chorionic plate, 405 
composed primarily of fetal cells, and the basal plate, consisting of a mixture 406 
of fetal (trophoblast) and maternal cells. In an investigation, portions of both 407 
plates were excised and homogenized; after removal of high Mr proteins by 408 
precipitation with acetonitrile, the supernatant, containing small proteins, 409 
peptides, lipids, and potentially other metabolites, was processed through LC-410 
MS analysis. Statistically significant differences were observed between the 411 
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two placental regions for 16 molecular species: of these, four were peptides, 412 
the remainders lipids [49]. 413 
The apical plasma membrane of the multinuclear syncytiotrophoblast features 414 
the human feto-maternal barrier and is the site of initial transport processes 415 
across the placenta. More than 170 integral and peripheral proteins were 416 
identified in isolated membranes, containing between 1 and 12 trans-417 
membrane domains or lipid anchors, and with functions as transporters or 418 
receptors, or involved in signal transduction processes and vesicular 419 
trafficking [50]. A follow-up investigation addressing the same subproteome 420 
(and using highly enriched preparations) lead to the identification of some 421 
more proteins, expanding the current proteomic database of the apical plasma 422 
membrane of the syncytiotrophoblast [51]. 423 
Another specialized material analyzed by 2DE-MS/MS was the culture of cells 424 
from chorionic villi, sampled during prenatal diagnosis of various fetal 425 
disorders: almost 300 proteins were identified, including enzymes, structural, 426 
signalling and carrier molecules [52]. 427 
 428 
Our group was involved in one of the first investigations on the proteome of 429 
amniotic fluid collected in gestational weeks 16-18. We concentrated our 430 
analysis on the Mr fraction < 50 kDa, obtained by gel filtration (and as such 431 
extensively depleted in albumin) [53]. The 2-DE map shown in Figure 2 was 432 
obtained under non-reducing denaturing conditions, which provide the best 433 
resolution among the sample components [54]. In this fraction we identified 33 434 
full-length proteins: 23 had never been previously detected in the amniotic 435 
fluid and, of these, 22 are not present in the human plasma proteome under 436 
physiological conditions. We also identified fragments of 16 larger proteins; 437 
from the sequence coverage data, several correspond to autonomous 438 
domains that may have biological roles on their own. Many of the detected 439 
proteins and peptides appear to be involved in critical regulatory processes 440 
associated with placentation and early development. 441 
In that same year (2007), amniotic fluid was investigated with different 442 
technical approaches. A free-flow technique based on isoelectric 443 
electrophoresis was used by Michel et al. [55], resulting in the identification of 444 
69 proteins: 26 of them were exclusively present in amniotic fluid and not in 445 
plasma of the same mother. Two types of 2D LC-MS/MS as well as LC-SDS-446 
PAGE-LC-MS/MS were instead used by Cho et al. [56], leading to the 447 
identification of a much larger number of proteins (as many as 842 non-448 
redundant proteins). A time course analysis of amniotic liquid shows changes 449 
in protein abundance with gestational age, the largest occurring between the 450 
first and second trimesters (572 out of 755 protein spots); among the proteins 451 
increasing in level: apo A-I, apo A-II, gamma-glutamyl transferase 4, IGFBPs, 452 
and pigment epithelial derived factor; among those decreasing in level: 453 
alpha2-HS-glycoprotein, angiotensinogen, ceruloplasmin, kininogen, 454 
orosomucoid, and ubiquitin; in addition to IGFBPs, transthyretin and vitamin D 455 
binding protein are present at very high levels throughout gestation [57]. 456 
 457 
It is known that the secretion of mammary glands changes with time. In late 458 
pregnancy and in the first days after childbirth it has the composition of 459 
colostrum: richer in proteins, vitamin A, and sodium, but poorer in 460 
carbohydrates, lipids, and potassium than mature milk. Bioactive components 461 
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in colostrum are growth factors, which stimulate the development of the gut, 462 
and antimicrobial factors - components of the adaptive (antibodies = IgA, IgG, 463 
IgM) and of the innate immune system (complement, lactoperoxidase, 464 
lactoferrin, lysozyme, and proline-rich polypeptides), together providing 465 
passive immunity against pathogens. Minor proteins in the aqueous phase of 466 
colostrum were identified after immunodepletion of the major components, to 467 
a total of ca.150 hits [58]; colostral fat globule membrane proteins were also 468 
investigated, to a total of ca.100 hits [59]. Comprehensive time-course 469 
surveys of the dynamic changes in milk protein abundance over a twelve-470 
month lactation period involved both whey [60] and fat globule membrane [61] 471 
fractions. 472 
The analysis of whey focused on low-abundance proteins, enriched by 473 
adsorption on ProteoMiner beads (reviewed in [62]), and identified by LC-474 
MS/MS after in-solution digestion [60]. Most identified proteins were involved 475 
in growth/maintenance, immunity support, lipid metabolism – the known key 476 
functions of breast feeding. As seen in Figure 3, some proteins (alpha-1-477 
antitrypsin, carbonic anhydrase, chordin-like protein 2, galectin-3-binding 478 
protein, lactadherin, lipoprotein lipase, and tenascin) are expressed at higher 479 
concentrations during early than during late lactation; others (fatty-acid 480 
binding protein, lysozyme C, monocyte differentiation antigen, proactivator 481 
polypeptide, transcobalamin-1, and zinc-R-2-glycoprotein) have an opposite 482 
trend. An investigation that also includes the major whey proteins but 483 
concentrates on the first six months after childbirth (weeks 1, 2, 3, 4, 8, 16, 484 
24) draws similar conclusions, with ca.10% of the identified proteins 485 
significantly changing in abundance with time. This includes serum albumin 486 
and fatty acid binding protein, which are involved in transporting nutrients to 487 
the infant; conversely, the decrease of the enzyme bile salt-activated lipase as 488 
well as the immunity proteins immunoglobulins and lactoferrin coincide with 489 
the gradual maturation of the digestive and immune system of the infants [63]. 490 
 491 
In addition to full-length proteins, milk contains large amounts of peptides. A 492 
comprehensive peptidomic investigation led to the identification of over 300 of 493 
them, most deriving from beta-casein (and none from lactoferrin, alpha-494 
lactalbumin, and IgA). From sequence data, several peptides with known 495 
antimicrobial or immunomodulatory functions could be recognized. Proteolytic 496 
events seem thus to provide substances able to protect both the mother's 497 
mammary gland and her nursing offspring from infection [64]. A systematic 498 
survey suggests a mechanistic perspective: proteolysis is selectively favored 499 
when able to release bioactive peptides and selectively prevented when it 500 
would hamper the protein’s function; presence of specific proteases, position 501 
and concentration of cleavage sites, and intrinsic disorder of segments of the 502 
protein are the factors contributing to the differential susceptibility to 503 
proteolysis [65]. 504 
Proteolytic cleavage in milk occurs after K and R residues (characteristic of 505 
plasmin or trypsin cleavage), after F, L, W or Y (pepsin- or chymotrypsin-like 506 
enzymes), after A, I, L, P, and V (cathepsin D or elastase) and at the termini 507 
of peptides (proline endopeptidase). In stomach aspirates sampled 2 h after 508 
feeding through a naso-gastric tube from infants who were hospitalized due to 509 
health problems unrelated to the gastrointestinal tract, a largely similar 510 
assortment of peptides was observed, with enrichment, however, in cleavage 511 
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after F, L, W, and Y and low frequency of further cleavage after K and R 512 
residues [66]. 513 
Other specific components analyzed from human milk are the proteins in 514 
extracellular vesicles (submicron-sized formations released by cells for 515 
intercellular communication) [67], and the N-glycoproteome of the milk fat 516 
globule (in a cross-species comparison involving six farm animals) [68]. An 517 
earlier application of proteomics to this field had been in the evaluation of 518 
proteins from different mammalian species looking for suitable substitutes for 519 
breast milk for infants allergic to cow’s milk-based formulas [69]. 520 
 521 
2.1.3 Pathological aspects of pregnancy 522 
 523 
Due to their frequent occurrence [70] and the severity of the sequels, 524 
hypertensive disorders of pregnancy have been extensively investigated, 525 
including proteomic tools. 526 
 527 
There is little doubt that the dysregulation of systemic and local blood flow 528 
typical of pre-eclampsia/eclampsia originates from placenta. In all 529 
pathological cases, placental tissue is available in large amounts soon after 530 
symptoms develop due to the need of emergency delivery of the babies of 531 
affected mothers. Accordingly, much of the current evidence comes from the 532 
analysis of placentas; the final goal of this area of investigation, however, 533 
remains the identification of one or a few biomarker(s) that may be easily 534 
evaluated in the blood of pregnant women and that predict(s) the 535 
development of the pathological condition in advance of overt, life-threatening 536 
symptoms. 537 
Having gone through the lists of differential proteins, the conclusion is – as for 538 
many other sample types – that no obvious overlap exists between the 539 
findings of different investigations. The likely reasons are connected with the 540 
different analytical procedures used in either case (1-DE [71], 2-DE [72, 73], 541 
2D LC [74]), but also with the alternatives in sample procurement and 542 
processing. Indeed, whole placental tissue implies a heavy burden of blood (a 543 
prominent hemoglobin spot dominates the proteomic pattern in [72]) and the 544 
finding of serum components among the differential proteins. This problem is 545 
much reduced focusing the analysis on trophoblast tissue, microdissected by 546 
laser capture [71, 74]: this technique, associated with 2D LC-MS/MS after 547 
ICAT labeling, resulted in the so far most exhaustive list of differentially 548 
regulated proteins. Trophoblast proteins detected at higher or lower 549 
concentrations in pre-eclampsia placentas are listed in Table 1 [74]. N-550 
glycoproteome phosphoproteome and nitroso proteome of pre-eclamptic vs 551 
normotensive placentas have also been studied [75, 76]. 552 
 553 
Table 1 – Proteins detected at significantly different concentrations in pre-eclamptic vs 554 
normotensive placentas * 555 
 556 
proteins at higher concentrations  
in pre-eclampsia placentas 
proteins at lower concentrations  
in pre-eclampsia placentas 
protein name fold change protein name 
fold 
change 
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Fraser syndrome 1 isoform 2 13.7 lamin B1 100.0 
pancreatic tumor-related protein 13.7 clathrin heavy chain 100.0 
KIAA0226 protein 9.3 laminin β-2 chain 12.5 
anti-pneumococcal antibody A7 
light chain variable region 8.7 
fibronectin 1 isoform 3 
preproprotein 9.1 
DNA-dependent protein kinase 
catalytic subunit 8.6  laminin β-2 chain precursor 9.1 
ADAMTS-like 3 8.0 fibrillin 8.3 
osteonidogen 8.0 laminin M chain 7.7 
low density lipoprotein-related 
protein 1 7.3 fibrillin 1 6.7 
immunoglobulin κ light chain 5.9 laminin α-5 chain 6.3 
ENO1P protein 5.8 laminin γ-1 chain 5.6 
coagulation factor XIIIb 5.8 laminin M chain 5.6 
 fibulin-1 A 5.7 Cd-7 Metallothionein-2 (β-domain) 4.8 
mitogen-activated protein kinase 
kinase kinase 5 5.7 heparin sulfate proteoglycan 3.7 
human elongation factor 2 5.3 migration stimulation factor FN70 2.9 
nidogen 4.8 EGF-like domain 2.3 
porin 31HM 4.6 integrin α-6 subunit 2.2 
tenascin XB 1 4.5 annexin VII isoform I 2.1 
myosin heavy chain 4.2   
plasminogen 3.6   
chaperonin (HSP60) 3.5   
collagen type XIV 3.2   
fibulin-1 A 2.9   
 557 
* on laser-capture microdissected trophoblast tissue processed through 558 
iTRAQ 2D LC-MS/MS [74]  559 
 560 
A very interesting perspective in terms of both, scientific insight and diagnostic 561 
applications of the proteomics findings, is provided by a prospective study 562 
addressing the high-to-medium-abundance serum proteins at 20 weeks of 563 
gestation in women who later developed pre-eclampsia; the group was further 564 
sorted into women giving birth to babies with either an appropriate or a small 565 
birth weight for gestational age, and compared to healthy controls with 566 
uncomplicated pregnancies [77]. The technical approach was DIGE on 567 
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samples immunodepleted of the most abundant components. The differential 568 
proteins are involved in lipid metabolism, complement cascade, coagulation, 569 
inflammation, extracellular matrix remodeling, protease inhibition and heme 570 
scavenging. The authors postulate that many of the identified proteins may be 571 
mediators or regulators of the maternal vascular, inflammatory and 572 
coagulation responses to placenta-derived triggers and may reflect a 573 
susceptibility to the condition. One half of the differential items overlap with 574 
proteins found in complex with high-density lipoproteins and linked to 575 
cardiovascular disease, confirming a connection between the different types 576 
of vascular dysfunction. 577 
A more recent investigation took a different approach: during the discovery 578 
phase, samples drawn at the 15th week of pregnancy and eventually pooled 579 
depending on later development of pre-eclampsia or absence of health 580 
problems, were immunodepleted of the top-abundance proteins, then trypsin 581 
digested and iTRAQ labeled; the resulting peptides were processed through 582 
2D LC and MALDI-TOF/TOF. Based on the results of the discovery phase, a 583 
label-free selected reaction monitoring workflow was defined, with the 584 
identification of some peptides, derived from platelet basic protein (also 585 
known as CXCL7) and pregnancy-specific glycoprotein, as potential predictive 586 
markers of early-onset pre-eclampsia [78]. 587 
 588 
Other investigations addressed instead pregnancy-induced hypertension 589 
[79] and could identify a few proteins, among the differential signals they 590 
detected (alpha-2-HS-glycoprotein, fibrinogen alpha, kininogen-1, some – 591 
undefined – complement component). Of some relevance, the authors of this 592 
study warn that the levels of most of the differential peptides were significantly 593 
decreased by albumin+IgG depletion, a standard procedure before 594 
proteomics analysis of serum. 595 
Finally, an investigation compared pregnancy-induced hypertension and 596 
eclampsia for their effects on the urinary proteome [80]. The differential 597 
proteins were connected with such biological processes as blood coagulation, 598 
cell adhesion and differentiation, immune response and cytoskeleton 599 
development. 600 
 601 
Recurrent pregnancy loss is defined by the occurrence of at least 3 602 
pregnancy losses in series prior to 20 weeks from the last menstrual period; it 603 
affects 1% to 2% of women. A recent investigation compared placental villi 604 
from women who have undergone early pregnancy loss and from age-605 
matched women undergoing intentional terminations of pregnancy at the 606 
same gestational age. About 10% of the ca. 6,000 identified proteins were 607 
found differentially regulated; the differential proteins participated in a variety 608 
of signaling pathways, including focal adhesion and ribosome pathway [81]. 609 
An earlier work applied 2-DE to decidual cells and recognized sustained 610 
endoplasmic reticulum stress in pathological samples, including decreased 611 
levels of glucose-regulated protein 78 and valosin-containing protein, and a 612 
high burden of ubiquitinated proteins [82]. In an investigation by 2-DE on 613 
serum samples from women facing recurrent pregnancy loss, 3 proteins 614 
(alpha-1-antichymotrypsin, alpha-2-macroglobulin, and insulin-like growth 615 
factor-binding protein 1) were found at increased levels whereas inter-alpha 616 
trypsin inhibitor-heavy chain 4 was found at reduced concentrations in the 617 
15 
 
native 120 kDa form and at increased levels in the form of a 36 kDa fragment 618 
[83]. 619 
 620 
Finally, preterm birth, defined as delivery before 37 weeks of gestation, 621 
affects 15 million infants born each year, varying from ca. 5% to 18% of all 622 
births across different countries worldwide. In the US, it is the leading cause 623 
of neonatal death and the second-leading cause of death in children before 5 624 
years of age. Preterm birth is also a major source of long-term health 625 
problems, including chronic lung disease, hearing and visual impairments, 626 
and neurodevelopmental disabilities, such as cerebral palsy. Prior history of 627 
spontaneous preterm delivery is currently the single strongest predictor of 628 
subsequent events: after a prior preterm delivery, the probability of a second 629 
is 30 to 50%. Other maternal risk factors include black race, low maternal 630 
body mass index, and short cervical length. 631 
In a proteomic investigation, preterm birth was found associated with serpin 632 
B7 [84]. In another it was found to correlate with insulin-like growth factor-633 
binding protein 4 and sex hormone-binding globulin: the former being found at 634 
higher, the latter at lower circulating levels in the time span between the 635 
beginning of the 19th and the end of the 21th week of gestation, in women who 636 
incurred preterm delivery [85]. The ratio between the two biomarkers was 637 
assessed as predictor of preterm birth: Figure 4 shows the Kaplan-Meyer plot 638 
for mothers diagnosed at low vs high risk for preterm delivery as well as the 639 
receiver operating characteristic curve for the predictor. 640 
 641 
A connected investigation explored instead cervical-vaginal fluid looking for 642 
proteomic markers of preterm labor. 2D LC-MS/MS and 2D-DIGE identified 28 643 
and 17 proteins, respectively, as potential biomarkers for the development of 644 
new tests for the early, noninvasive positive prediction of preterm birth. The 645 
short list of overlapping findings between the two approaches includes: 646 
annexin A3; calgranulin A and B; cystatin A; fatty acid-binding protein, 647 
epidermal; heat-shock protein beta-1; 14-3-3 protein sigma [86]. 648 
 649 
2.2 Male items 650 
 651 
No investigations have been devoted to tissue specimens if not in the context 652 
of comparative analyses of health vs disease samples – most often of 653 
samples from fertile vs infertile subjects. 654 
 655 
Current evidence suggests that, in addition to deliver the packaged male DNA 656 
to the oocyte, sperm provides a specific epigenetically marked genome 657 
together with a complex population of RNAs as well as proteins that are 658 
crucial for early embryogenesis. The seminal fluid itself appears to serve 659 
multiple roles, providing a series of supplementary components that allow the 660 
sperm to successfully reach and fertilize the oocyte and prepare the female 661 
immune system to tolerate the semiallogenic embryo [87]. 662 
 663 
The components of seminal plasma have been individually identified [88, 89] 664 
and then analyzed in association with sperm functional alterations. In a 665 
detailed investigation, three such parameters were monitored - mitochondrial 666 
activity alterations, acrosome damage and DNA fragmentation. Proteomic 667 
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investigation was carried out through LC-MS and the results were statistically 668 
evaluated through univariate and multivariate analysis. This led to the 669 
identification of a small number of markers, positively or negatively correlated 670 
with each of the three conditions (Table 2) [90]. 671 
 672 
Table 2 – Seminal plasma biomarkers of sperm functional traits (from Table 2 in [90]) 673 
 674 
trait protein name protein function(s) 
vari- 
co-
celea 
mitochondrial 
activity alteration 
annexin A7 - regulation of exocytosis - anti-apoptotic effect  
endoplasmic reticulum 
resident protein 44 
- protein disulfide bonds 
formation and 
rearrangement 
- cell redox homeostasis 
 
glutathione S-transferase mu 
3 
- acrosome action and 
fertilization 
- reactive oxygen species 
detoxification 
K
acrosome damage phospholipid transfer protein 
- binding to vitamin E 
- regulation of phospholipid 
exchange in lipoproteins 
 
DNA fragmentation proteasome subunit alpha type-5 
- protein degradation 
- removal of sperm with 
damaged DNA 
Kb 
DNA integrity 
cysteine-rich secretory 
protein LCCL domain-
containing 1 
- cellular adhesion 
- fertilization  
cysteine-rich secretory 
protein LCCL domain-
containing 2 
- cellular adhesion 
- fertilization 
- anti-inflammatory effect 
uni-
late-  
ral 
retinoic acid receptor 
responder protein 1 - tumor suppression  
 675 
a from Table 1 in [91] 676 
b proteasome subunit alpha type-7-like  677 
 678 
Unfortunately, none of the proposed markers coincides with those listed in 679 
[92] as differentiating the seminal plasma from fertile and infertile males when 680 
the samples were processed through SELDI-TOF MS after adsorption on a 681 
strong anion exchanger. Conversely, three at least partial matches are 682 
observed with the proteins associated with reproductive function differentially 683 
expressed in men with unilateral vs bilateral varicocele (rightmost column in 684 
Table 1) [91]. In this latter case, the analytical procedure was 1-DE followed 685 
by LC-MS; technical replicates were run on pooled samples. It is all too 686 
obvious from the above that individual exploratory tests based on different 687 
inclusion/exclusion criteria for control and/or patient selection, on different 688 
protocols for sample handling, on different proteomics approaches can at 689 
most hint to the definition of useful biomarkers. Only a systematic review on 690 
the findings may eventually lead to a consensus practice and to the 691 
development of suitable diagnostic tests. 692 
 693 
Seminal plasma collects secretions from different districts of the male genital 694 
tract. The contribution from the prostate has been singled out in some 695 
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reports; for instance, after in solution digestion, prostasomes, membrane-696 
bound storage vesicles found in prostate epithelial cells, have been analyzed 697 
by µLC-MS/MS [93] whereas expressed prostatic secretions have been by 698 
MudPIT [94]. 699 
 700 
Spermatozoa are transcriptionally and translationally silent, and may be 701 
characterized only via a proteomic approach. The most relevant conditions to 702 
contrast in this respect are normo- and asthenozoospermia, as defined with 703 
reference to sperm motility. Shotgun analysis of samples from a few fertile 704 
and infertile subjects led to the identification of hundreds of proteins. Principal 705 
component analysis on differential proteins (Anova p value < 0.05 and fold 706 
change > 2) resulted in a complete separation of the samples into two clusters, 707 
normozoospermic and asthenozoozpermic. No such separation could be 708 
obtained using proteomic data collected in parallel on seminal plasma 709 
samples from the same subjects. The most relevant differential proteins are 710 
the following: dynein light chain 1, cytoplasmic; fascin-3; leucine-rich repeat-711 
containing protein 37B; ninein; PHD finger protein 3; plexin-B2; protein 712 
PROCA1; putative beta-actin-like protein 3. Some of the enriched pathways 713 
are then: axoneme activation and focal adhesion assembly, glycolysis, 714 
gluconeogenesis, cellular response to stress and nucleosome assembly [95]. 715 
Clusters found in sperm data by Self-Organizing Maps (SOM) [96] are shown 716 
in Figure 5 in the form of Venn’s diagram.  717 
A complementary approach to the above evaluation comes from the 718 
comparison between sperm subpopulations fractionated from 719 
normozoospermic samples on the basis of differential motility (non-migrated 720 
vs migrated spermatozoa in a swim-up setting). Similar proteomic alterations 721 
were detected in the two experiments (80 proteins differentially abundant in 722 
the two groups of samples and 93 differentially abundant in the two groups of 723 
subpopulations); involved proteins were associated with energetic metabolism, 724 
protein folding/degradation, vesicle trafficking, or were cytoskeletal 725 
components [97]. 726 
Consistently with the focus on motion, the comparison between normo- and 727 
asthenozoospermic semen samples was later narrowed to an investigation on 728 
sperm tails [98]. Differences were observed for 21 spots, corresponding to 14 729 
proteins – none overlapping with items in the above list. An earlier study had 730 
analyzed the two compartments of heads and flagella, identifying > 500 731 
proteins as unique to the former and > 700 proteins as unique to the latter [99]. 732 
Another specialized survey had focused on sperm glycocalyx, assessed with 733 
the use of a lectin microarray (among 91 tested lectins, 16, 13, 24 and 37 734 
showed strong, medium, weak and negative binding, respectively) [100]. A 735 
parallel investigation had been carried out on the N-linked glycoproteome of 736 
human seminal plasma, using glycosylated peptide enrichment, combined 737 
with LC-MS/MS analysis [101]. Glycosylation is just one of the several PTMs 738 
occurring in spermatozoa. Protein synthesis is switched off long before the 739 
sperm is mature and spermatozoa may only rely on PTMs of existing proteins 740 
as a way to modulate their proteome [102, 103]. Freshly ejaculated sperm 741 
acquires the fertilizing potential by a continuing process, termed capacitation, 742 
that occurs during sperm transport through the female genital tract, and is 743 
physiologically not complete until the spermatozoon reaches the oocyte. From 744 
the above, quali- and quantitative differences observed between the 2DE 745 
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maps of freshly ejaculated vs 3-h in vitro capacitated sperm should only 746 
involve re-assortment among different protein species; this includes the 747 
effects of proteolysis, as flagellar organization proteins were found decreased 748 
during capacitation whereas their cleaved fragments increased [104]. 749 
Different PTM seem to serve different functions: N-terminally acetylated 750 
proteins and non-modified proteins appear to be more associated with the 751 
basic cellular functions, whereas acetylated, phosphorylated, and 752 
glycosylated proteins are more directly involved in specialized sperm 753 
functions [105]. Lysine acetylation is essential for sperm motility and 754 
fertilization as shown by the interference in such processes by histone 755 
acetylase inhibitors and anti-acetyllysine antibodies [106]. Lysine 756 
acetylproteome was compared between uncapacitated and capacitated sperm 757 
[107, 108]; different acetylation profiles were observed for functional proteins 758 
involved in sperm capacitation, sperm-egg recognition, sperm-egg plasma 759 
fusion, and fertilization. Phosphorylation, as resulting from the balance 760 
between the catalytic action of kinases [109] and phosphatases [110], is also 761 
of key importance in the mechanisms of sperm maturation and capacitation. 762 
Among the over 200 sites with increased phosphorylation levels during sperm 763 
capacitation, PTM of insulin growth factor 1 receptor seems to play a pivotal 764 
role [111]. 765 
Another mechanism to modify the properties of spermatozoa, and chiefly their 766 
ability to interact with zona pellucida as the first step towards oocyte 767 
fertilization, is for existing proteins to organize into multimeric complexes. This 768 
hypothesis was investigated by blue native polyacrylamide gel electrophoresis 769 
(BN-PAGE) and led to the identification of the 20S proteasome and 770 
chaperonin-containing TCP-1 (CCT) complexes [112]. 771 
 772 
2.3 Cancer of the sexual organs 773 
 774 
As we state in the Introduction, among the physiology/pathology issues this 775 
review on the proteomics data for sexual organs aims to focus on 776 
fertility/infertility rather than on health/disease at large. However, cancer of the 777 
sexual organs deserves a mention, both because of its relevance as medical 778 
and social issue and because proteomic investigations are especially active in 779 
the field (we could retrieve a total of > 3400 original publications and >700 780 
reviews overall; source: https://www.ncbi.nlm.nih.gov/pubmed/). Available 781 
evidence is being consolidated in a Cancer Proteomics database [113]; other 782 
repositories of relevant information are The Cancer Genome Atlas, for ovarian 783 
and endometrial cancer [114], and BCCTBbp: the Breast Cancer Campaign 784 
Tissue Bank bioinformatics portal [115]. 785 
While the number of publications per cancer type reflects the incidence of the 786 
various forms (new cases per year in the US, source: 787 
https://www.cancer.gov/), the lines along which the research is moving are 788 
similar irrespective of the organ being affected by the disease. Of course the 789 
identification of the proteins and protein species differing in concentration 790 
between physiological and pathological tissues, and among different subtypes 791 
of the pathological tissues, is one essential step; proteomic evidence is 792 
sometimes supported by transcriptomic and/or genomic data. More and more 793 
often, however, the analysis targets specific subproteomes, e.g. glycoproteins 794 
(with altered glycan composition) and/or membrane proteins, or exosomes. 795 
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Specific protocols are being devised for the study of archival samples. Due to 796 
the difficulties of assessing disease markers in the general circulation, 797 
investigations are being devoted to fluids collected in closer proximity to the 798 
affected organ, trading ease of procedures for specificity of protein content; 799 
urine is also investigated as an accessible alternative to serum. Table 3 800 
categorizes along these lines a selection of papers published in the most 801 
recent years on four cancer types: cancer of cervix, endometrium, breast and 802 
prostate.  803 
 804 
Table 3 – Recent publications on cancer in sexual organs 805 
 806 
organ research area specimen procedure references 
cervical 
cancer 
overall 
proteome tissue iTRAQ & LC-MS/MS [116] 
overall 
proteome tissue 2D-DIGE & MS [117] 
alternative 
biological fluids cervical smear iTRAQ & LC-MS/MS [118] 
alternative 
biological fluids 
cervicovaginal 
fluid 
label-free shotgun 
2D-LC/MS [119] 
endometrial 
cancer  
overall 
proteome tissue 
integrated genomics, 
transcriptomics and 
proteomics 
[120] 
subtyping aneuploid vs diplod cells 2DE & MS [121] 
archival 
samples tissue 
laser microdissection 
& mTRAQ LC-
MS/MS 
[122] 
archival 
samples tissue 
laser microdissection 
& shotgun LC-
MS/MS 
[123] 
subproteomes membranes iTRAQ & LC-MS/MS [124] 
subproteomes exosomes functional proteomics [125] 
alternative 
biological fluids uterine aspirate 
data mining & LC-
MS/MS [126] 
alternative 
biological fluids 
fluid fraction of 
uterine aspirate targeted proteomics [127] 
alternative 
biological fluids urine 2DE & MS [128] 
alternative 
biological fluids urine 
N-glycopeptide 
profiling by 
SELDI-TOF 
[129] 
breast cancer 
subtyping secreted proteins 
transcriptomics & MS 
proteomics [130] 
subtyping tissue label-free shotgun 2D-LC/MS [131] 
subtyping 
archival 
samples 
archive 
samples (and 
cultured cells) 
SILAC cell culture, 
shotgun LC-MS/MS [132] 
archival 
samples  
label free shotgun 
LC-MS/MS [133] 
subproteome membranes  [134] 
subproteome membranes label free LC-MS/MS [135] 
subproteome secreted proteins 2DE & antibodies [136] 
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subproteome exosomes tandem-mass-tag proteomics [137] 
circulating 
markers serum 
antibodies & label-
free LC-MS/MS [138] 
alternative 
biological fluids urine label free LC-MS/MS [139] 
prostate 
overall 
proteome tissue 2D-DIGE & MS [140] 
overall 
proteome tissue 
transcriptomics & Ab-
profiling [141] 
overall 
proteome 
archive 
samples (and 
cultured cells) 
SILAC cell culture, 
shotgun LC-MS/MS [142] 
subtyping tissue immunofluorescence [143] 
subtyping cell lines 
label free shotgun, 
CITP and CZE, LC-
MS/MS 
[144] 
subtyping 
archival 
samples 
biopsies multiplex proteomics imaging [145] 
subtyping tissue cell lines 2D-DIGE & MS [146] 
subproteome glycoproteins iTRAQ & LC-MS/MS [147] 
subproteome exosomes label-free shotgun LC-MS/MS [148] 
subproteome exosomes aptamer-based array platform [149] 
subproteome 
alternative 
biological fluids 
exosomes 
urine 
label-free shotgun 
LC-MS/MS [150] 
circulating 
markers serum antibody microarrays [151] 
circulating 
markers serum 
depletion-free iTRAQ 
3D LC/MS [152] 
alternative 
biological fluids seminal plasma 
capillary 
electrophoresis & MS [153] 
 807 
3 Conclusions 808 
 809 
We can repeat here one statement from the Conclusions of the accompanying 810 
review [1]: In most cases evidence gathered thus far may only be regarded as 811 
preliminary. A leap forward, from proof-of-concept to steady knowledge, 812 
requires statistically robust data collected under highly standardized 813 
conditions. Collaborative efforts shared by institutions and convergence 814 
among disciplinary approaches may be regarded as the rational route to 815 
problem solving. 816 
 817 
 818 
Figure legends 819 
 820 
Figure 1 – Myometrium proteins that show a statistically significant increase 821 
(left) or decrease in S-nitrosation (middle and right) during preterm labor. 822 
Legend: ALBU, serum albumin; ANXA6, annexin A6; CLIC1, chloride 823 
intracellular channel protein 1; CNN1, calponin-1; GSTP1, glutathione S-824 
transferase P; HBB, hemoglobin subunit beta; HBD, hemoglobin subunit 825 
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delta; LEG1, galectin-1; LPP, lipoma-preferred partner; MYL6, myosin light 826 
polypeptide 6; MYL9, myosin regulatory light polypeptide 9; MYLK, myosin 827 
light chain kinase, smooth muscle; PALLD, palladin; PDLI1, PDZ and LIM 828 
domain protein 1; PGR, progesterone receptor; PROF1, profilin-1; TAGL, 829 
transgelin-1; THIO, thioredoxin; VINC, vinculin. Redrawn from Figures 4 and 5 830 
in [35]. 831 
 832 
Figure 2 – Reference map of the low molecular mass proteins of amniotic fluid 833 
run under non-reducing, denaturing conditions. Main identifications are 834 
marked with protein full names or with UniProt codes. Experimental: 1d on 4-835 
10 NL IPG [154] in 8 M urea without reduction, 2d on 10-17%T PAA according 836 
to Schägger and von Jagow [9]; 300 µg protein with molecular mass lower 837 
than albumin; Coomassie stain. Modified from Figure 2 in [53]. 838 
 839 
Figure 3 – Heat map presentation of spectral counting data. Colors represent 840 
the scaled fold-change of spectrum counts between samples within a row 841 
(same protein at different time points). Modified from Figure 4 in [60]. 842 
 843 
Figure 4 – Assessment of a predictor of preterm birth based on insulin-like 844 
growth factor-binding protein 4 and sex hormone-binding globulin 845 
concentrations in serum. Top panel: Kaplan-Meier estimator of high- and low-846 
risk groups. Subjects at or above 2× the background risk (14.6%) are 847 
considered high-, those below 2× low-risk. Bottom panel: ROC plot of 848 
sensitivity vs (1 – specificity), in which preterm delivery cases are defined as 849 
delivery ≥ 37 weeks and term controls as delivery ≤37 weeks gestational age. 850 
The AUROC corresponds to 0.72. Redrawn form Figures 4 and 5 in [85]. 851 
 852 
Figure 5 – Venn’s diagram summarizing the relationships among sperm 853 
proteins. Clusters found by Self-Organizing Maps (SOM). From Figure 9 in 854 
[95]. 855 
 856 
 857 
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